Osteolytic lesions marker in multiple myeloma

Med Oncol. 2011 Mar;28(1):237-40. doi: 10.1007/s12032-010-9432-4. Epub 2010 Feb 2.

Abstract

The degradation product of collagen type I carboxy terminal telopeptide (ICTP) represents a new biochemical parameter that reflects the changes in the resorption properties of skeletal system. Affection of the skeleton is one of the most important characteristics of multiple myeloma (MM). We estimated significance of ICTP as osteolysis predictor and overall survival in comparison with standard prognostic parameters β(2)-microglobulin and C-reactive protein (CRP), in patients with MM. With our results, we have shown significant difference in serum level of ICTP (P = 0.009) between patients with and without osteolysis on conventional radiography. It was proved that ICTP is the most significant predictor of osteolysis (P = 0.09), while CRP is the most significant risk factor for overall survival (P < 0.01). Being highly significant predictor of osteolysis, ICTP can be used for identification of patients with MM who had increased risk for developing osteolytic lesions.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • C-Reactive Protein / metabolism
  • Collagen Type I / blood*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / blood*
  • Multiple Myeloma / pathology*
  • Osteolysis / blood*
  • Osteolysis / pathology*
  • Peptides / blood*
  • Prognosis
  • Survival Rate
  • beta 2-Microglobulin / blood

Substances

  • Biomarkers, Tumor
  • Collagen Type I
  • Peptides
  • beta 2-Microglobulin
  • collagen type I trimeric cross-linked peptide
  • C-Reactive Protein